Who Benefits Most? Smart Patient Selection Explained

Understanding patient selection is essential to achieving optimal outcomes in the management of benign prostatic hyperplasia (BPH). In this section, leading experts share how they evaluate patients for therapies such as HoLEP, GreenLight laser therapy, and Rezūm™ Water Vapour Therapy. Gain valuable insights into tailoring treatment pathways for men with enlarged prostate and learn about real-world factors that impact decision-making.

Dr G. Muir & Dr F. Kum: Patient Centricity with High-Risk BPH Patients

This podcast material is for informational purposes only and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health. This podcast was produced in cooperation with Dr Muir and Dr Kum. Results from case studies are not predictive of results in other cases. Results in other cases may vary.

Dr N. Coull & Dr M. Johnston: Role of the Patient in BPH Therapy Selection Process

This podcast material is for informational purposes only and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health. This podcast was produced in cooperation with Dr Coull and Dr Johnston. Results from case studies are not predictive of results in other cases. Results in other cases may vary.

Dr K. Saeb-Parsy & Dr F. Kum: Challenges and Opportunities for Patients in the Post-COVID Era

This podcast material is for informational purposes only and and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health. This podcast was produced in cooperation with Mr Saeb-Parsy and Mrs Kum. Results from case studies are not predictive of results in other cases. Results in other cases may vary.

Go back to main Podcasts page

Reference list

  1. Robert G, Cornu JN, Fourmarier M, Saussine C, Oescazeaud A, Azzouzi AR, Vicaut E, Lukacs 8. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016 Mar:117(3):495-9. doi: 10.1111/bju.13124. Epub 2015 Aug 22. PMID: 25781490. 
  2. Kampantais S, Dimopoulos P, Tasleem A, Acher P, Gordon K, Young A. Assessing the Learning Curve of Holmium Laser Enucleation of Prostate {HoLEP). A Systematic Review. Urology. 2018 Oct;120:9-22. doi: 10.1016/j.urology.2018.06.012. Epub 2018 Jul 4. PMID: 30403609. 
  3. Aho T, Herrmann TR. Description of a modular mentorship programme for holmium laser enucleation of the prostate. World J Urol. 2015 Apr;33(4):497-502. doi: 10.1007/s00345-014-1407-1. Epub 2014 Oct 1. PMID: 25271105
  4. Wollin TA, Denstedt JD. The holmium laser in urology. J Clin Laser Med Surg. 1998 Feb;16 (1):13-20. doi: 10.1089/clm.1998.16.13. PMID: 9728125. 
  5. Ramadhani MZ, Kloping YP, Rahman IA, Yogiswara N. Renaldo J, Wirjopranoto S. Comparative efficacy and safety of holmium laser enucleation of the prostate {HoLEP) using moses technology and standard HoLEP: A systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond). 2022 Aug 12;81:104280. doi: 10.1016/j.amsu.2022.104280. PMID: 36147079; PMCID: PMC9486436.
  6. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan March 2023. ISBN 978-94-92671-19-6. 
  7. AUA Sandhu JS, Bixler BR, Dahm P. et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023. J Urol. 2023;10.1097/JU.0000000000003698. https :// doi.org/10.1097 /JU.0000000000003698 
  8. Shah HN, Sodha HS, Kharodawala SJ, Khandkar AA. Hegde SS. Bansal MB. Influence of prostate size on the outcome of holmium laser enucleation of the prostate. BJU Int. 2008 Jun:101(12):1536-41. doi: 10.1111/j.1464-410X.2007.07434.x. Epub 2008 Jan 24. PMID: 18218057. 
  9. Kuntz RM, Lehrich K. Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008 Jan;53{1}:160-6. doi: 10.1016/j.eururo.2007.08.036. Epub 2007 Aug 28. PMID: 17869409. 
  10. Ahyai SA, Gilling P, Kaplan SA. Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ. Stief CG. Metaanalysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010 Sep;58(3):384-97. doi: 10.1016/j.eururo.2010.06.005. Epub 2010 Jun 11. PMID: 20825758. 
  11. Nam JK, Kim HW, lee DH, Han JY, lee JZ, Park SW. Risk Factors for Transient Urinary Incontinence after Holmium Laser Enucleation of the Prostate. World J Mens Health. 2015 Aug;33(2):88-94. doi:10.5534/wjmh.2015.33.2.88. Epub 2015 Aug 19. PMID: 26331125; PMCID: PMC4550601. 
  12. EIHakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int. 2002 Dec;90{9):863-9. 
    US and EU (excluding France) 05/22 Clinical Large T, Nottingham C, Stoughton C, et al.Com
  13. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019 Apr;126:171-9. 
  14. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Sep;206(3):715-24. 
  15. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline 2021. J Ural. 2021 Oct;206:806-26. 
  16. Woo HH, Gonzalez RR. Perspective on the Rezūm® System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices (Auckl). 2017;10:71-80. 
  17. Danielle Whiting a, Mohamed Noureldin , Yehia Abdelmotagly, Maximilian J. Johnston, James Brittain, Govindaraj Rajkumar, Amr Emara, Richard Hindley, Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia, EUROPEAN UROLOGY OPEN SCIENCE39(2022)72-78 
  18. Daniel Bassily BS, Rezūm for retention-retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia, The Prostate. 2021;1-6.
  19. Dean S. Elterman, Zorn, MD, et al. Rezum water vapor therapy for catheterdependent urinary retention: a real-world Canadian experience, The Canadian Journal of Urology'"; 29(2); April 2022 
  20. K. Eredics, l. Lusuardi et al, Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency, Prostate Cancer and Prostatic Diseases (2022) 25:302 -305 
  21. Kevin T. McVary et al., Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia, Prostate Cancer and Prostatic Diseases (2020) 23:303-308 
  22. Theodoros Spinas et al., Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature, World Journal of Urology (2023) 41:413-420